Anesthetic Agents
PreclinicalSmall molecule
Anesthetic Agents is one of 23 small molecule programs targeting Subarachnoid Hemorrhage. It is currently in Preclinical.
1
Indications
4
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Subarachnoid Hemorrhage
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Cardene
Sun Pharmaceutical Industries, Inc.Approved
Olumiant
Eli LillyApproved
Pletal
OtsukaApproved
Neurontin
VViatris Specialty LLC
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Heparin Sodium
BBaxter Healthcare Corporation
Approved
Ketalar
AAultman Health Foundation
Approved
Angiomax
BBaxter Healthcare Corporation
Approved
Marcaine
IInnocoll
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Subarachnoid Hemorrhage1 trial
Pediatric Patients1 trial
The Effect Of Positive End-Expiratory Pressure on Optic Nerve Sheath Diameter In Pediatric Patients Undergoing Craniotomy in Supine Position
Completed·—·N/A·NCT07370779·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anesthetic Agents. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMassachusetts General Hospital